AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01897714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melflufen
Study NCT01897714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT04864301 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent Stretching Measurement Technique
Description: The Tumescent Stretching Measurement Technique (TSMT) group (N=12) will be administered an intracorporal injection (ICI) of 20 microgram Alprostadil. Hegar 7 dilator will be introduced through the corporotomy until reaching a bone stopping point. The tumescent penis will stretched maximally, and the proximally inserted dilator measured externally to the coronal sulcus.
Study NCT03102333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Variable-rate Feedback Infusion mode
Description: The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
Study NCT03102333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Constant-rate Infusion mode
Description: The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
Study NCT03124446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based College
Description: MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
Study NCT03124446 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Control
Description: Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
Study NCT03332290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sport practice
Description: the intervention was a training course lasting 10 days. It included 10 days of sports practice. For divers, diving was carried out using air at a maximum depth of 40-meters, with a maximum of one dives a day. For the multisport group (the non-divers), the course included kayaking, mountain climbing or hiking with a maximum of two activities a day.
Study NCT03332290 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sport practice
Description: the intervention was a training course lasting 10 days. It included 10 days of sports practice. For divers, diving was carried out using air at a maximum depth of 40-meters, with a maximum of one dives a day. For the multisport group (the non-divers), the course included kayaking, mountain climbing or hiking with a maximum of two activities a day.
Study NCT04680091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate
Description: single oral dose, 400 mg, fed.
Study NCT04680091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrotinib Maleate
Description: single oral dose, 400 mg, fed.
Study NCT02979990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructional Video
Description: The experimental group will be asked to view a set of videos that demonstrate proper usage of controlled ovarian stimulation medication. They will have the opportunity to review instructional videos as needed throughout the ovarian stimulation process.
Study NCT02979990 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Video
Description: The control group will have access to a video about the IVF process
Study NCT02686775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient coach
Study NCT04680091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: single oral dose, 600 mg, fasted, at bedtime.
Study NCT02236442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendation to use global headache treatment protocol
Description: The global treatment protocol is :~1. Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor~2. Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.~3. Provide a sound-proof helmet to the patient.~4. Provide a light-blocking google to the patient.~5. If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.~6. If judged necessary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :~Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidal anti inflammatory or paracetamol or triptan.~Tension headache : nonsteroidal anti inflammatory or paracetamol. Avoid methylmorphine or tramadol if possible.~Cluster headache : Intravenous or nasal spray sumatriptan and oxygen therapy.~Other etiology : Treatment left at the discretion of the physician in charge of the patient.
Study NCT04236479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-MSC
Description: Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.
Study NCT03740841 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interactive story teller LUNII
Description: Use of the interactive story teller LUNII by the child from the pre-operative visit to the discharge.
Study NCT02734602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be administered after the initial PET scan for subjects participating in the ketamine aim.
Study NCT02686775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Study NCT02686775 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study NCT01528800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K1
Description: 10mg orally three times a week for 12 months
Study NCT01528800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Methylcellulose
Description: 10mg orally three times a week for 12 months
Study NCT01193348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
Study NCT02988076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEER Interactive Report
Description: A subinvestigator treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. A subinvestigator treating a Control Group subject will NOT receive the PEER Report and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
Study NCT03286361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeGraft Peripheral Plus Stent Graft System
Description: Patients will be treated with the BeGraft Peripheral Plus Stent Graft System
Study NCT04471727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6070
Description: IV infusion
Study NCT04471727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: IV infusion
Study NCT04471727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ifinatamab Deruxtecan (I-DXd)
Description: IV infusion
Study NCT04904549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)
Description: Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection
Study NCT04904549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)
Description: Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
Study NCT04904549 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: liquid. Route of administration: intramuscular administration.
Study NCT04904549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
Description: Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
Study NCT04904549 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination
Description: Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
Study NCT02969564 — intervention group
Intervention type: OTHER
Intervention: scintigraphy 99mTc-MDP-SPECT/CT.
Description: SPECT/CT will be performed for every patient in the frame of their clinical follow up
Study NCT02969564 — intervention group
Intervention type: OTHER
Intervention: 18F-NaF-PET/MR
Description: a 18F-NaF-PET/MR will be performed, in the frame of this clinical study, to the patients to assess the difference of sensitivity of the 2 exams
Study NCT03526172 — intervention group
Intervention type: PROCEDURE
Intervention: High tibial osteotomy
Description: Uni-lateral medial opening-wedge high tibial osteotomy following a minimally invasive approach.
Study NCT03526172 — intervention group
Intervention type: DEVICE
Intervention: Allograft wedge
Description: Insertion of allograft wedge into the osteotomy gap during the HTO procedure
Study NCT03526172 — intervention group
Intervention type: DEVICE
Intervention: Accelerometer
Description: ActivPal accelerometer attached to thigh of patient to collect objective physical activity data at pre-determined intervals before and after surgery
Study NCT03526172 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Validated clinical questionnaires administered to patients to collect subjective physical activity data at pre-determined intervals before and after surgery
Study NCT01380080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla (r)
Description: Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
Study NCT01380080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Participants will take one 600 mg tablet administered orally once daily without food.
Study NCT01380080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
Study NCT01380080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin/isoniazid/pyrazinamide/ethambutol FDC
Description: Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
Study NCT01380080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin/isoniazid FDC
Description: Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
Study NCT01380080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH 300 mg orally once daily
Study NCT04581083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR
Description: RT-PCR (Gold standard): Real-time PCR testing with reverse transcriptase (RT-PCR). The test consists of a polymerase chain reaction that has previously had a reverse transcription phase, RT. This test allows the cADN (complementary DNA) to be obtained from a RNA chain. This technique allows the detection and amplification of a sequence from a strand of RNA.
Study NCT04581083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LAMP
Description: LAMP: The LAMP technique, like PCR, has the ability to amplify specific DNA fragments (target sequence), allowing for highly sensitive detection of pathogens. Unlike pcr, LAMP requires between 4 and 6 feeders, external F3 and B3 feeders, which hybridte with the outer regions of the target sequence, while the internal FIP and BIP have sequences in both ways that allow the formation of a loop. The LAMP reaction is isothermal, i.e. it takes place at a single temperature. LAMP has been successfully used to detect viral diseases as well as viral pathogens such as West Nile virus, TMR-1, Norovirus, avian influenza, foot-and-mouth disease, classical swine fever, among others.
Study NCT04581083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: POOL RT-PCR
Description: POOL RT-PCR: This test aims to mix in a single sample the extractions obtained from several people. The joint sample is evaluated and, if negative, it is understood that all are free of COVID-19; if it is positive, an array system is used to detect the affected person. That is, a single PCR (polymerase chain reaction), the diagnostic test used to detect the virus pathogen is applied to a group and repeated individually if positive.
Study NCT04581083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: POOL LAMP
Description: POOL LAMP: Like the RT-PCR pool test. This test essentially involves mixing in a single sample the extractions obtained from several people. This joint sample is tested and, if it is negative, it is understood that everyone is free of COVID-19; if it is positive, an array system is used to detect the affected person. That is: a single LAMP applies to a group
Study NCT02185768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Study NCT02185768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dc- Beads 300-500µm
Study NCT04499053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: durvalumab 1500 mg, intravenous, every 3 weeks for 4 cycles, followed by 1500 mg, intravenous, every 4 weeks (maintenance treatment)
Study NCT04499053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: tremelimumab 75 mg, intravenous, every 3 weeks for 4 cycles. A dose of tremelimumab 75 mg will be given at week 16.
Study NCT02599896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB080-00-AB (VRC01LS)
Description: VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
Study NCT02599896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB060-00-AB (VRC01)
Description: VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
Study NCT03642119 — intervention group
Intervention type: DEVICE
Intervention: iButton®
Description: Women with frequently reported hot flashes will be undergo both real world (ambulatory; field tests) and controlled (laboratory) assessments to validate the iButton® as an objective method to assess hot flash dynamics and incidence.
Study NCT00988559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccination
Description: vaccination with pNGVL4a-CRT/E7(detox)
Study NCT02197299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00988559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gene gun vaccine
Description: 8 micrograms (group 1) or 16 micrograms (group 2)
Study NCT00988559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intramuscular vaccination
Description: 1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
Study NCT00988559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intra-lesional vaccine administration
Description: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
Study NCT00988559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic resection of the lesion
Description: at week 15, all residual lesions will be resected
Study NCT00751036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib hard gel capsules were supplied to the Investigators at dose strengths of 200 mg. Nilotinib is a novel agent, which has been approved for the treatment of chronic phase and accelerated phase Philadelphia-chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
Study NCT00751036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib tablets were supplied at 100 mg and/or 400 mg dose strength. Imatinib is an approved agent for GIST. Efficacy of imatinib at a dose of 400 mg bid has been established in the setting of disease progression after the use of the conventional dose (400 mg qd).
Study NCT03673579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICU Dashboard
Description: The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
Study NCT03106350 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.
Study NCT01830231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
Study NCT01830231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinflunine
Description: Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:~* 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of~* 280 mg/m2 in patients aged >75 - ≤80 years or with PS 1 or prior pelvic radiation,~* 250 mg/m2 in patients aged >80 years.
Study NCT03468803 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Beta D Glucan test
Description: Measurement of BDG before, during and after surgery
Study NCT03566862 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Leicester Cough Monitor (LCM)
Description: The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.
Study NCT00988559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod
Description: imiquimod applied to the cervix by the physician
Study NCT01267097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.
Study NCT01267097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-Education Program (PEP)
Description: PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
Study NCT00618683 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac Invasive Electrophysiological Study
Description: Mapping and localizing of the components of the reentrant circuit as part of the Electrophysiological Study